Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease

Research output: Contribution to journalArticle

Abstract

Crohn's disease (CD) causes chronic inflammation of the gastrointestinal tract and leads to fluctuations between active disease and remission. Certolizumab pegol is one of the newer biological treatments for patients with moderate-to-severe CD. Certolizumab pegol was shown to be effective in CD patients achieving response and remission in both randomized and non-randomized studies, and is an alternative biological treatment for CD. The available data show that certolizumab pegol achieves similar therapeutic efficacy and health-related quality of life scores in CD patients as the other biological agents, but at a higher cost, if dose escalation of other biologics is not considered. Considering subcutaneous self-administration, and lower number and frequency of injections, patients may prefer certolizumab pegol over the other biological treatments.

Original languageEnglish (US)
Pages (from-to)599-609
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number5
DOIs
StatePublished - Oct 1 2014

Keywords

  • Crohns disease
  • biologics
  • certolizumab pegol
  • inflammatory bowel disease

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease'. Together they form a unique fingerprint.

  • Cite this